Identification
Instrument name
NOXXON
Symbol
ALNOX
ISIN code
NL0012044762
Exchange / Market
Euronext Growth
Trading location
Paris
Products family
Stocks
Market organization
Alternext
ICB
Biotechnology
Website address
Operation
IPO date
IPO price
EUR 21.34
Issue type
Private placement
Catégorie
IPO

Company profile

NOXXON Pharma NV is a clinical-stage biopharmaceutical company specialized in the research and development of therapeutic products intended for the treatment of cancers. NOXXON's Spiegelmer® platform has generated a proprietary pipeline of clinical-stage product candidates including its lead cancer drug candidate NOX-A12, which is the subject of a clinical immuno-oncology collaboration agreement with Merck & Co. / MSD to study NOX-A12 combined with MSD's anti-PD-1 checkpoint-inhibiting antibody Keytruda® in pancreatic and colorectal cancer.

Source: Cofisem - Last Update: 24 Apr 2020
Key Executives
Chief Executive Officer Aram Mangasarian
Investor Relations Alexia Faure
Source: Cofisem - Last Update: 06 May 2019
Key figures
Millenium 2017 2016 2015 2014
Net sales 83 43 25
Income from ordinary activities 83 43 25
Operating income -4,730 -8,599 -14,830 -13,166
Cost of net financial indebtedness
Equity-Accounted companies' contribution to results
Net profit from discontinued activities
Net income -5,390 -10,752 -16,102 -13,798
Net income (group share) -5,385 -10,747 -16,102 -13,798
Fiscal year end 12.17 12.16 12.15 12.14
Length of fiscal year (month) 12 12 12 12
Currency & Unit EUR - thousands EUR - thousands EUR - thousands EUR - thousands
Account Standards
Source: Cofisem - Last Update: 24 Apr 2020
Shareholder information
Acuitas Capital 35,9 %
Kreos Capital 12,7 %
TVM Capital 4,3 %
DEWB 3,4 %
NGN BioMed 2,8 %
Others 40,9 %
Free float 7.20 %
Seventure Partners 3.90 %
Thomas Van Aubel 3.70 %
Beteiligungsgesellschaft Sachsen-Anhalt 2.50 %
Source: NOXXON Pharma NV - Last Update: 14 Jan 2019